Schizophrenia and liver dysfunction

Medical Hypotheses

Volumn 56, Issue 5, 2001, Pages 634-636

  Kroll, J ^a  

^a BLEKINGE HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; AUTOPSY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DOPPLER ECHOGRAPHY; HUMAN; LIVER DYSFUNCTION; PATHOGENESIS; PORTOSYSTEMIC ANASTOMOSIS; PRIORITY JOURNAL; SCHIZOPHRENIA; TECHNIQUE;

EID: 0034980155     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1054/mehy.2000.1254     Document Type: Article

References (57)

1. Stéathose hépatique ches les aliénés
2. The amino-hepato-entero-toxic theory of schizophrenia: An historical evaluation
3. Schizophrenia triggered by hepatitis A
4. Schizophrenieahnliche Symptomatik bei der Westphal-Strumpell-Verlaufsform des Morbus Wilson
5. The neuropsychiatric syndromes associated with chronic liver disease and an extensive portal-systemic collateral circulation
6. Liver dysfunction and schizophrenia
7. Portal-systemic shunts and mental disorders
8. Portal-systemic encephalopathy in the noncirrhotic patient. Effect of portal-systemic shunting
9. Regional alterations of dopamine and its metabolites in rat brain following portacaval anastomosis
10. Concentrations of 3,4-dihydroxyphenylalanine and catecholamines and metabolites in brain in an anhepatic model of hepatic encephalopathy
11. Developing a neuronal model for the pathophysiology of schizophrenia based on the nature of electrophysiological actions of dopamine in the prefrontal cortex
12. Regional brain monoamines and their metabolites after portacaval shunting
13. Raised plasma concentrations of 3-methoxy-4-hydroxyphenylethyleneglycol in cirrhotic patients with or without hepatic encephalopathy
14. Plasma 3-methoxy-4-hydroxyphenylglycol changes associated with clinical state and schizophrenic subtype
15. Studies of catecholamine metabolism in schizophrenia/psychosis - I
16. Biochemistry and the schizophrenias
17. Brain histamine levels and neocortical slow-wave activity in rats with portacaval anastomosis
18. Histamine and prostaglandins in schizophrenia: Revisited
19. Preliminary evidence of low cortical GABA levels in localized 1H-MR spectra of alcohol-dependent and hepatic encephalopathy patients
20. Measurement of GABAergic parameters in the prefrontal cortex in schizophrenia: Focus on GABA content, GABA(A) receptor alpha-1 subunit messenger RNA and human GABA transporter-1 (HGAT-1) messenger RNA expression
21. GABA and brain abnormalities in schizophrenia
22. Effects of portacaval anastomosis on glucose tolerance in the dog: Evidence of an interaction between the gut and the liver in oral glucose dosposal
23. The effect of portacaval anastomosis on oral carbohydrate tolerance and on plasma insulin levels
24. Positron emission tomography studies of abnormal glucose metabolism in schizophrenia
25. Glucose metabolic correlates of continuous performance test performance in adults with a history of infantile autism, schizophrenics, and controls
26. The influence of portosystemic shunt operation on immunoglobulins and Escherichia coli antibodies in patients with cirrhosis of the liver
27. E. coli antibodies in schizophrenia
28. Antibody titre changes and skin reactivity in patients with liver cirrhosis undergoing portocaval shunt operation
29. Antiretroviral antibodies: Implications for schizophrenia, schizophrenia spectrum disorders, and bipolar disorder
30. Fast resolution of hypercortisolism in dogs with portosystemic encephalopathy after surgical shunt closure
31. Platelet serotonin, plasma cortisol, and dexamethasone suppression test in schizophrenic patients
32. Development of a method to monitor low molecular mass hydrocarbons in exhaled breath of man: Preliminary evaluation of its interest for detecting a lipoperoxidation process in vivo
33. The lipid membrane hypothesis of schizophrenia: Implications for possible clinical breath tests
34. Changes in free radicals, trace elements, and neurophysiological function in rats with liver damage induced by D-galactosamine
35. Free radical pathology and antioxidant defense in schizophrenia: A review
36. Oxidative reactions and schizophrenia: A review-discussion
37. The blood-brain barrier to horseradish peroxidase under normal and experimental conditions
38. Early changes in the permeability of the blood-brain barrier produced by toxins associated with liver failure
39. Blood-CSF barrier permeability and central nervous system immunoglobulin G in schizophrenia
40. Blood-cerebrospinal fluid barrier impairment as indicator for an immune process in schizophrenia
41. Chronic acquired hepatocerebral degeneration: Case reports and new insights
42. Neuropsychological impairment in a patient with a normal liver and long-standing portacaval anastomosis: Studies obtained before and after liver transplantation
43. Biological markers for the schizophrenic and atypical psychoses
44. Meta-analyses of studies of ventricular enlargement and cortical sulcal prominence in mood disorders. Comparisons with controls or patients with schizophrenia
45. Structural magnetic resonance image averaging in schizophrenia
46. Progressive atrophy of the frontal lobes in first-episode schizophrenia: Interaction with clinical course and neuroleptic treatment
47. Stereological studies of the schizophrenic brain
48. A prospective evaluation of changes in neuropsychological and liver function tests following transjugular intrahepatic portosystemic stent-shunt
49. Large spleno-caval shunt not accompanied by cirrhosis or encephalopathy
50. Patency of the ductus venosus and disease
51. Testosterone as well as estrogen increases serotonin2A receptor mRNA and binding site densities in the male rat brain
52. Gonadectomy in adult life increases tyrosine hydroxylase immunoreactivity in the prefrontal cortex and decreases open field activity in male rats
53. Ultrasound diagnosis of portocaval anastomosis in infants-a report of eight cases
54. Extrahepatic portal-systemic encephalopathy without portal hypertension
55. Three brothers with progressive hepatic dysfunction and severe hepatic steatosis due to a patent ductus venosus
56. Treatment of hepatic encephalopathy by retrograde transcaval coil embolization of an ileal vein-to-right gonadal vein portosystemic shunt